Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actelion Ltd's Psoriasis Drug Meets Main Goal In Trial-Reuters


Tuesday, 18 Dec 2012 04:38am EST 

Dow Jones reported that Actelion Ltd reported positive results from a mid stage clinical trial of a treatment for skin disease psoriasis. The Company said on Tuesday its ponesimod drug achieved its main goal in the trial, with 46% of patients suffering from moderate to severe chronic plaque psoriasis seeing a 75% improvement in an index for monitoring the disease at 16 weeks when treated with a 20 milligramme dose. 

Company Quote

113.6
0.1 +0.09%
4:22am EDT